Vertex deal with Wales expands cystic fibrosis treatment coverage to all of UK
Share:
(Reuters) - Vertex Pharmaceuticals Inc's drugs for lung condition cystic fibrosis will now be available to patients across the UK after the company reached a pricing deal with Wales on Wednesday. The U.S. drugmaker has already reached similar agreements with the National Health Service in Northern Ireland, England and Scotland.More than 10,000 people in Britain have cystic fibrosis, a debilitating, life-shortening inherited condition, making it the country with the second highest number of such..